1. Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease
- Author
-
Fitzpatrick, RL, Wittenburg, LA, Hansen, RJ, Gustafson, DL, and Quimby, JM
- Subjects
Male ,Kidney Disease ,Liver Diseases ,Subcutaneous ,Liver Disease ,Age Factors ,Cat Diseases ,Ondansetron ,Injections ,Cats ,Animals ,Antiemetics ,HIV/AIDS ,Female ,Renal Insufficiency ,Veterinary Sciences ,Chronic ,Digestive Diseases - Abstract
Ondansetron, a 5-HT3 receptor antagonist, is an effective anti-emetic in cats. The purpose of this study was to compare pharmacokinetics of subcutaneous (SQ) ondansetron in healthy geriatric cats to cats with chronic kidney disease (CKD) or liver disease using a limited sampling strategy. 60 cats participated; 20 per group. Blood was drawn 30 and 120min following one 2mg (mean 0.49mg/kg, range 0.27-1.05mg/kg) SQ dose of ondansetron. Ondansetron concentrations were measured by liquid chromatography coupled to tandem mass spectrometry. Drug exposure represented as area under the curve (AUC) was predicted using a limited sampling approach based on multiple linear regression analysis from previous full sampling studies, and clearance (CL/F) estimated using noncompartmental methods. Kruskal-Wallis anova was used to compare parameters between groups. Mean AUC (ng/mL·h) of subcutaneous ondansetron was 301.4 (geriatric), 415.2 (CKD), and 587.0 (liver). CL/F (L/h/kg) of SQ ondansetron was 1.157 (geriatric), 0.967 (CKD), and 0.795 (liver). AUC was significantly higher in liver and CKD cats when compared to geriatric cats (P 
- Published
- 2016